» Articles » PMID: 15233659

Use of Intravenous Proton Pump Inhibitors in Community Practice: an Explanation for the Shortage?

Overview
Specialty Gastroenterology
Date 2004 Jul 6
PMID 15233659
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Since 2001, one intravenous proton pump inhibitor (pantoprazole) has been available in the United States. A drug shortage bulletin was issued for this agent in 2003.

Aim: To evaluate the patterns of use of intravenous proton pump inhibitors (IV PPIs) in routine clinical practice.

Methods: Prospective evaluation of IV PPI use in two community-based teaching hospitals. A computerized pharmacy ordering system was used to identify all patients for whom an IV PPI was ordered. Trained investigators obtained clinical data from patient records and these data were mapped to establish clinical criteria for the use of IV PPIs.

Results: Intravenous PPIs were prescribed in 238 patients over a 30-day period and a total of 1,631 doses were prescribed. Primary care providers prescribed 46% of prescriptions. Fifty-six percent of patients who received IV PPIs had no acceptable indication for their use. Of the 126 (81%) patients who were started on PPIs for the first time during their hospital stay, 102 were discharged on a PPI.

Conclusions: Intravenous PPIs are widely used for poor indications, which may contribute to the shortage of these agents.

Citing Articles

Predictive Factors Associated with Inappropriate Intravenous Proton Pump Inhibitors Use in Hospitalized Patients: A Case-Control Study.

Khoury N, Stepensky D, Abu Freha N, Mahamid M, Khoury T, Mari A Medicina (Kaunas). 2025; 61(1).

PMID: 39858992 PMC: 11767144. DOI: 10.3390/medicina61010010.


Drug utilization evaluation of pantoprazole in Kempegowda Institute of Medical Sciences (KIMS) hospital and research centre, India.

Ghorbani S, Nagaraju K J Family Med Prim Care. 2022; 11(6):3138-3142.

PMID: 36119255 PMC: 9480637. DOI: 10.4103/jfmpc.jfmpc_1516_21.


Research Into the Effect of Proton Pump Inhibitors on Lungs and Leukocytes.

Ozatik O, Ozatik F, Teksen Y, Dag I, Saygili S, Kocak A Turk J Gastroenterol. 2021; 32(12):1003-1011.

PMID: 34876390 PMC: 8975296. DOI: 10.5152/tjg.2021.20550.


The Pattern of Intravenous Proton-Pump Inhibitor Utilization at an Academic Medical Center in Riyadh, Saudi Arabia.

Mohzari Y, Alsaegh A, Asdaq S, Al Shanawani S, Albraiki A, Bagalb A J Res Pharm Pract. 2021; 9(3):151-154.

PMID: 33489984 PMC: 7808177. DOI: 10.4103/jrpp.JRPP_20_62.


Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.

Luo H, Fan Q, Xiao S, Chen K BMC Health Serv Res. 2018; 18(1):537.

PMID: 29996830 PMC: 6042351. DOI: 10.1186/s12913-018-3358-5.